RedHill Biopharma Balance Sheet Health
Financial Health criteria checks 3/6
RedHill Biopharma has a total shareholder equity of $61.0K and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $22.0M and $22.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$7.28m |
| Equity | US$61.00k |
| Total liabilities | US$21.96m |
| Total assets | US$22.02m |
Recent financial health updates
Recent updates
This Is Why RedHill Biopharma Ltd.'s (NASDAQ:RDHL) CEO Compensation Looks Appropriate
Sep 10
RedHill Biopharma Ltd. (NASDAQ:RDHL) Might Not Be As Mispriced As It Looks
Jul 28One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts
Nov 24RedHill Biopharma receives Nasdaq notification regarding minimum bid price deficiency
Oct 18RedHill wins EU’s orphan drug status to RHB-204 for rare lung disease
Aug 17RedHill: Given Up For Dead
Apr 30RedHill Biopharma: Looking At An Unexciting Dead-End
Dec 30Financial Position Analysis
Short Term Liabilities: RDHL's short term assets ($15.7M) do not cover its short term liabilities ($21.2M).
Long Term Liabilities: RDHL's short term assets ($15.7M) exceed its long term liabilities ($730.0K).
Debt to Equity History and Analysis
Debt Level: RDHL is debt free.
Reducing Debt: RDHL had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RDHL has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: RDHL has less than a year of cash runway if free cash flow continues to grow at historical rates of 5.9% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 05:24 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
RedHill Biopharma Ltd. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| null null | BTIG |
| Brandon Folkes | Cantor Fitzgerald & Co. |